Rapport Therapeutics Capital Raise of $216M
Rapport Therapeutics entered into an underwriting agreement for a public offering of 8,333,334 shares of common stock and 1,190,476 pre-funded warrants at a price of $21.00 per share. The underwriters fully exercised their option to purchase an additional 1,428,571 shares, bringing estimated net proceeds to approximately $215.7 million. The funds are intended to support clinical trials for RAP-219 and other research and development activities.
- Value
- $216M
- Counterparty
- Morgan Stanley & Co. LLC